Dr Reddys Laboratories (RDY) EBT (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly EBT of $230.0 million for Q2 2023, up 2.22% quarter-over-quarter from $225.0 million in Q1 2023.

Dr Reddys Laboratories (RDY) EBT (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' EBT history runs 15 years deep, the most recent figure standing at $230.0 million for Q2 2023.

In Q2 2023, EBT changed N/A year-over-year to $230.0 million; the TTM figure through Jun 2023 stood at $617.0 million (changed N/A YoY), while the FY2026 annual figure was $584.0 million, down 35.11% from the prior year.
EBT for Q2 2023 stood at $230.0 million, up from $225.0 million in the prior quarter.
The five-year high for EBT was $230.0 million in Q2 2023, with the low at -$72.0 million in Q3 2020.
The 5-year median for EBT is $119.0 million (2019), against an average of $113.5 million.
The sharpest annual moves came in 2019 and 2020: EBT soared 73.91% in 2019, then plunged 188.89% in 2020.
Dr Reddys Laboratories' EBT stood at $81.0 million in 2019, then slumped by 188.89% to -$72.0 million in 2020, then jumped by 337.5% to $171.0 million in 2021, then decreased by 5.26% to $162.0 million in 2022, then surged by 41.98% to $230.0 million in 2023.
Business Quant data shows RDY's EBT at $230.0 million in Q2 2023, $225.0 million in Q1 2023, and $162.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-455.00 Mn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	866.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	1.02 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	372.70 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	-64.00 Mn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	162.20 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	56.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	-1.88 Mn

Download Data